Hyderabad: After dithering for weeks, the World Health Organization (WHO) finally provided an emergency use listing (EUL) to the Covid-19 vaccine, Covaxin, on Wednesday, on Wednesday.
The agreement came as a major pause for millions of Indians who were vaccinated with an inactive virus vaccine but faced restrictions on the way abroad.
Now those who have received two doses of Covaxin can travel abroad without having to undergo quarantine.
“Who has provided an emergency use list (EUL) to #Covaxin (developed by Bharat Biotech), adding a vaccine portfolio that developed validated by who for Prevention # Covid19,” the global health agency tweeted on Wednesday night.
NOD came after who the technical advisory group (tag) met again on Wednesday to carry out the final risk-benefit analysis of the vaccine after the previous meeting on October 26.
Also read Covaxin’s Covaxin gets whatnew Delhi: World Health Organization: (Who) on Wednesday approved the Covid-19 vaccine made in India developed by Bharat Biotech.
The WHO decision has been welcomed by the government.
This is what says: Bharat Biotech: Vaccine developers, Bharat Biotech said that the strategic consultation expert group about immunization (SAGE) had met on October 5 to recommend vaccines.
However, after tweeting on October 5 that will take the last call in Covaxin the following week, which has delayed the provincial approval of certain aspects related to vaccines.
Developer Covaxin Bharat Biotech has submitted his expression on April 19 this year and the sending of rolling data starts on July 6 in India and now has emerged as a dominant variant globally.
Phase-3 trials were carried out in almost 26,000 people in India.
Covaxin has been part of the Indian National Immunization Program even when the phase-3 trial was underway after it was awarded an emergency use authorization (EUA) by Indian drug regulators on January 3.